CSF ACR 2022 - Congress Preview (RA)
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>ACR</strong> <strong>2022</strong><br />
<strong>Congress</strong> <strong>Preview</strong><br />
Rheumatoid Arthritis<br />
Steering Committee Introduction<br />
Dear Colleagues,<br />
Welcome to my selection of the <strong>ACR</strong> abstracts for <strong>RA</strong>.<br />
This year’s <strong>ACR</strong> presents several insightful and interesting presentations in rheumatoid arthritis (<strong>RA</strong>). This includes 63<br />
abstracts, within which we have highlighted 27 that are we found to be most interesting. This includes data on JAK<br />
inhibitor switching as well as an integrated safety analysis of filgotinib. Indeed, <strong>ACR</strong> <strong>2022</strong> offers those interested in <strong>RA</strong><br />
therapeutics a wide range of interesting presentations across the conference.<br />
Among the Day 1 abstracts there are a number of presentations we recommend you attend. Many of these interesting<br />
presentations are included in <strong>RA</strong>-Treatment Poster Session 1. There are two new studies on treatment switching (0274<br />
& 0304), as well as a presentation on the impact of upadacitinib and adulimumab on pain (0297). Long-term 6.9-year<br />
efficacy data of baricitinib from <strong>RA</strong>-BEYOND has been presented by Roberto Carorali and Daniel Aletaha (0272). We<br />
also highly recommend the three filgotinib studies in <strong>RA</strong>, collectively covering safety clinical outcomes, and radiographic<br />
changes over time (0273, 0281 & 0299).<br />
Day 2 offers a number of interesting presentations about clinical interventions for <strong>RA</strong>. These include two presentations<br />
focusing on tofacitinib which we suggest you attend (1107 & 1586), as well as some posters on treatment cycling (1427<br />
& 1588). Jacques-Eric Gottenberg will be leading a presentation showcasing long term data on the association between<br />
acute cardiovascular events in <strong>RA</strong> with tofacitinib or TNFis (1429).<br />
Safety data is also a theme of the presentations on Day 3. Long term data on malignancies related to tofacitinib<br />
therapy as well as well as the impact of baracitinib on bone biochemical properties (1995). For those interested in novel<br />
therapeutics we also recommend two posters, one discussing the novel dazodalibep (2008), the other highlighting data<br />
from the BEGIN study on theAP1189, a MC type 1 and 3 agonist (1985).<br />
As always thank you for your continued support,<br />
Kind regards<br />
Professor Janet Pope<br />
SPONSORSHIP AND UNRESTRICTED EDUCATIONAL G<strong>RA</strong>NTS FROM<br />
Register for FREE content at www.cytokinesignalling.com<br />
DEVELOPED UNDER<br />
THE AUSPICES OF THE<br />
Follow us at:<br />
Cytokine Signalling Forum
Key Presentations<br />
Editor’s Picks<br />
Saturday, 12 November <strong>2022</strong><br />
13:00–<br />
15:00<br />
1648<br />
16:00–<br />
16:10<br />
510<br />
13:00–<br />
15:00<br />
0198<br />
13:00–<br />
15:00<br />
0046<br />
13:00–<br />
15:00<br />
0267<br />
13:00–<br />
15:00<br />
0296<br />
0272<br />
0273<br />
0275<br />
POSTER SESSION<br />
<strong>RA</strong> – DIAGNOSIS, MANIFESTATIONS,<br />
AND OUTCOMES<br />
Risk of Vascular Events Under the Treatments with Janus<br />
Kinase Inhibitors in Patients with Rheumatoid Arthritis: An<br />
Analysis Using Japanese Health Insurance Database<br />
Eiichi Tanaka<br />
O<strong>RA</strong>L SESSION<br />
MISCELLANEOUS RHEUMATIC AND INFLAMMATORY<br />
DISEASES I<br />
MACE and VTE Across Upadacitinib Clinical Trial Programs<br />
in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing<br />
Spondylitis<br />
Christina Charles-Schoeman<br />
POSTER SESSION<br />
PATIENT OUTCOMES, PREFERENCES, AND<br />
ATTITUDES POSTER I<br />
Patient Perspectives on Janus Kinase Inhibitor Use in the<br />
Treatment of Inflammatory Arthritis<br />
Savia de Souza<br />
POSTER SESSION<br />
<strong>RA</strong> – ANIMALS MODELS POSTER<br />
Baricitinib Ameliorates Residual Neuropathic Pain in Collagen<br />
Antibody-Induced Arthritis Mice by Suppressing Inflammation<br />
of the Dorsal Root Ganglion<br />
Kenta Makabe<br />
POSTER SESSION<br />
<strong>RA</strong> – DIAGNOSIS, MANIFESTATION AND OUTCOMES<br />
POSTER I<br />
Cancer Risk with Biologic and Targeted Synthetic DMARDs in<br />
Patients with Rheumatic Diseases and Previous Malignancy:<br />
Results from the BIOBADASER Register<br />
Juan Molina<br />
POSTER SESSION<br />
<strong>RA</strong> – TREATMENT POSTER I<br />
Characteristics and Treatment-selection in Patients with<br />
Rheumatoid Arthritis and with Inadequate Response to Janus<br />
Kinase Inhibitors<br />
Yusuke Miyazaki<br />
Long-Term Efficacy of Baricitinib in Patients with Rheumatoid<br />
Arthritis with Inadequate Response to Bdmards: Results from<br />
<strong>RA</strong>-BEYOND up to 6.9-Years of Treatment<br />
Roberto Caporali & Daniel Aletaha<br />
An Update on the Integrated Safety Analysis of Filgotinib in<br />
Patients with Moderately to Severely Active <strong>RA</strong><br />
Kevin Winthrop<br />
Exploratory Analysis of Filgotinib Safety Data in Patients with<br />
Moderately to Severely Active <strong>RA</strong> and an Increased Risk of<br />
Cardiovascular Events: Data from Phase 2 and 3 Clinical Trials<br />
Maya Buch<br />
0277<br />
274<br />
0282<br />
0286<br />
0293<br />
0294<br />
0295<br />
0297<br />
0299<br />
0304<br />
0274<br />
0276<br />
0279<br />
Malignancy Events in the Filgotinib Rheumatoid Arthritis and<br />
Ulcerative Colitis Clinical Development Programs<br />
Xavier Mariette<br />
Clinical Outcomes of Filgotinib in Patients with <strong>RA</strong> Aged ≥65<br />
Years: A Post Hoc Subgroup Analysis of Phase 2 and 3 Clinical<br />
Trials and Ongoing Long-Term Extensions<br />
Maya Buch<br />
Efficacy and Safety of Upadacitinib in TNFi-IR Patients with<br />
Rheumatoid Arthritis from Three Phase 3 Clinical Trials<br />
Roy Fleischmann<br />
Efficacy and Safety of Upadacitinib in Patients Across Races<br />
with Rheumatoid Arthritis: A Post Hoc Analysis of Six Phase 3<br />
Clinical Trials<br />
Grace Wright<br />
Long-term Sustainability of Response to Upadacitinib Among<br />
Patients with Active Rheumatoid Arthritis Refractory to<br />
Biological Disease-Modifying Anti-Rheumatic Drugs: Results<br />
Through 5 Years from SELECT-BEYOND<br />
Ronald van Vollenhoven<br />
Safety and Efficacy of Upadacitinib in Patients with Rheumatoid<br />
Arthritis and Inadequate Response or Intolerance to Biologic<br />
DMARDs: Results Through 5 Years from the SELECT-BEYOND<br />
Study<br />
Roy Fleischmann<br />
Safety and Efficacy of Upadacitinib in Patients with Rheumatoid<br />
Arthritis and Inadequate Response to Conventional Synthetic<br />
DMARDs: Results Through 5 Years from the SELECT-NEXT<br />
Study<br />
Gerd Burmester<br />
Effect of Upadacitinib, Adalimumab, and Placebo on Residual<br />
Pain Among Patients with Rheumatoid Arthritis Whose<br />
Inflammation Was Attenuated After Three and Six Months of<br />
Treatment<br />
Louis Bessette<br />
Radiographic Change in Patients with Rheumatoid Arthritis and<br />
Estimated Baseline Yearly Progression ≥5 or < 5: Post Hoc<br />
Analysis of Two Phase 3 Trials of Filgotinib<br />
Yoshiya Tanaka<br />
Rheumatoid Arthritis Patients Who Switched Treatment from<br />
Adalimumab to Upadacitinib Demonstrate a Robust Reduction<br />
of Inflammation-related Biomarkers: Proteomics Analysis from<br />
the SELECT-COMPARE Phase 3 Study<br />
Thierry Sornasse<br />
Real-world Utilisation and Switching Between Janus Kinase<br />
Inhibitors in Patients with Rheumatoid Arthritis in the Australian<br />
OPAL Dataset<br />
Sabina Ciciriello<br />
Baseline Characteristics of and Early Outcomes in the First<br />
200 Patients with <strong>RA</strong> Treated with Filgotinib in a Prospective<br />
Observational Study<br />
James Galloway<br />
Effect of Filgotinib on Body Weight and BMI and Effect of<br />
Baseline BMI on the Efficacy and Safety of Filgotinib in <strong>RA</strong><br />
Alejandro Balsa
Editor’s Picks<br />
0280<br />
0285<br />
0288<br />
0289<br />
0290<br />
0292<br />
0298<br />
0300<br />
0301<br />
0302<br />
0303<br />
0305<br />
0287<br />
0291<br />
Safety of Filgotinib in Patients with <strong>RA</strong>: Laboratory Analysis<br />
Results from a Long-Term Extension Study<br />
Maya Buch<br />
Characteristics and Outcomes of Patients with Rheumatoid<br />
Arthritis Treated with Upadacitinib in a Global Real-World<br />
Setting<br />
Roberto Felice Caporali<br />
Comparison of the Effect of Different Janus Kinase Inhibitors<br />
on Activation, Function and Property of NK Cells to Control<br />
Cancer Cell Lines Proliferation: An Ex Vivo and in Vitro Study<br />
Loïc Meudec<br />
Real-world Data of Tofacitinib versus Tumor Necrosis Factor<br />
Inhibitors in Taiwanese Patients with Rheumatoid Arthritis from<br />
a Drug-based Registry<br />
Song-Chou Hsieh<br />
Evaluation of Treatment Discontinuation Due to Adverse<br />
Events, and the Effect of Cardiovascular Risk Factors or Type<br />
of JAK-inhibitors: An International Collaboration of Registries of<br />
Rheumatoid Arthritis Patients<br />
Kim Lauper<br />
Malignancy in the Upadacitinib Clinical Trial Programs for<br />
Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing<br />
Spondylitis<br />
Andrea Rubbert-Roth<br />
Effectiveness of Upadacitinib in Patients with Rheumatoid<br />
Arthritis in Canadian Real-World Practice: Interim Results from<br />
the CLOSE-UP Post-Marketing Observational Study<br />
Derek Haaland & Louis Bessette<br />
Exposure-Response Analyses of Upadacitinib Effects on<br />
Plasma Biomarkers in Rheumatoid Arthritis Patients<br />
Yuli Qian<br />
Effectiveness and Safety of Tofacitinib Treatment in Adult<br />
Patients with Rheumatoid Arthritis Under Routine Clinical<br />
Care: Third Interim Analysis of a German Non-Interventional,<br />
Prospective, Multicenter Study (ESCALATE-<strong>RA</strong>)<br />
Klaus Krüger<br />
Risk of Infections Between JAK Inhibitors and TNF Inhibitors<br />
Among Patients with Rheumatoid Arthritis<br />
Se Rim Choi<br />
Effectiveness of Upadacitinib in the Treatment of Rheumatoid<br />
Arthritis: Analysis of 6-Month Real-World Data from the United<br />
Rheumatology Normalized Integrated Community Evidence<br />
(UR-NICETM) Database<br />
Allan Gibofsky<br />
Effect of Upadacitinib on Bone Erosion Repair in Rheumatoid<br />
Arthritis: A Pilot Study<br />
Ho So<br />
Association Between Short-Term Response to Upadacitinib<br />
Treatment and Long-Term Clinical Outcomes in Patients with<br />
Rheumatoid Arthritis and Prior Inadequate Response to Tumor<br />
Necrosis Factor Inhibitor Therapy<br />
Christina Charles-Schoeman<br />
Tofacitinib Leads to Significant Weight Gain - A Real Life<br />
Experience of 429 Patients<br />
Naga Prabu<br />
Sunday, 13 November <strong>2022</strong><br />
09:00–<br />
10:30<br />
0584<br />
09:00–<br />
10:30<br />
0723<br />
09:00–<br />
10:30<br />
0908<br />
09:00–<br />
10:30<br />
0918<br />
0925<br />
10:30–<br />
12:00<br />
1107<br />
13:00–<br />
15:00<br />
1354<br />
13:00–<br />
15:00<br />
1375<br />
POSTER SESSION<br />
CYTOKINES AND CELL T<strong>RA</strong>FFICKING POSTER<br />
Non-Clinical Evaluations of Deucravacitinib and Janus Kinase<br />
Inhibitor Specificity in Inflammatory or Homeostatic Pathways<br />
Brandon Johnson<br />
POSTER SESSION<br />
EPIDEMIOLOGY AND PUBLIC HEALTH<br />
Risk of Major Adverse Cardiovascular and Venous<br />
Thromboembolism Events in Patients with Rheumatoid Arthritis<br />
Exposed to JAK Inhibitors versus Adalimumab: A Nationwide<br />
Cohort Study<br />
Lea Hoisnard<br />
POSTER SESSION<br />
DIAGNOSIS, MANIFESTATIONS, AND OUTCOMES<br />
POSTER II<br />
The Association of Cardiovascular Comorbidities with<br />
Remission in Rheumatoid Arthritis Patients Undergoing<br />
Treatment with Baricitinib and Conventional Synthetic<br />
DMARDs: A Post-Hoc Analysis<br />
Arkady Manning-Bennett<br />
POSTER SESSION<br />
<strong>RA</strong> – TREATMENT POSTER II<br />
Efficacy and Safety of Filgotinib in Patients with Inadequate<br />
Response to Methotrexate, with 4 or < 4 Poor Prognostic<br />
Factors: A Post Hoc Analysis of the FINCH 1 Study<br />
Bernard Combe<br />
Impact of Initiating Biologic and Targeted Synthetic Disease-<br />
Modifying Antirheumatic Drugs on Pain Medication Use in<br />
Patients with Rheumatoid Arthritis<br />
Mengdong He<br />
O<strong>RA</strong>L SESSION<br />
ABST<strong>RA</strong>CTS: MISCELLANEOUS RHEUMATIC AND<br />
INFLAMMATORY DISEASES II<br />
Efficacy and Safety of Tofacitinib in Patients with Polymyalgia<br />
Rheumatica (EAST PMR): A Prospective Study<br />
Xinlei Ma<br />
POSTER SESSION<br />
PATIENT OUTCOMES, PREFERENCES, AND<br />
ATTITUDES POSTER II<br />
Early Real-World Effectiveness of Upadacitinib in Rheumatoid<br />
Arthritis Using Patient-Reported Outcomes Collected via Mobile<br />
Application<br />
BLeslie Harrold<br />
POSTER SESSION<br />
PEDIATRIC RHEUMATOLOGY – CLINICAL POSTER II:<br />
CONNECTIVE TISSUE DISEASE<br />
Short-term Efficacy of Baricitinib in Children with Refractory<br />
And/or Severe Juvenile Dermatomyositis<br />
Zhaoling Wang & Meiping Lu
Editor’s Picks<br />
13:00–<br />
15:00<br />
1395<br />
1396<br />
1401<br />
1419<br />
1420<br />
1427<br />
1429<br />
1431<br />
15:15–<br />
15:25<br />
1586<br />
15:45–<br />
15:55<br />
1588<br />
16:15–<br />
16:25<br />
1590<br />
POSTER SESSION<br />
<strong>RA</strong> – DIAGNOSIS, MANIFESTATIONS, AND<br />
OUTCOMES POSTER III<br />
Comparative Safety of Janus Kinase Inhibitors and Tumor<br />
Necrosis Factor Inhibitors in Patients Undergoing Treatment for<br />
Rheumatoid Arthritis<br />
Yao-Fan Fang<br />
Risk of Hospitalized Infections in Older Elderly Rheumatoid<br />
Arthritis Patients Treated with Biological/Targeted Synthetic<br />
DMARDs: Evaluation Using Data from a Japanese Claims<br />
Database<br />
Masayoshi Harigai<br />
Relationship Between Disease Activity and Adverse Events of<br />
Interest in Patients with <strong>RA</strong> on Tofacitinib or TNF Inhibitors: Post<br />
Hoc Analysis of a Phase 3b/4 Randomized Safety Study<br />
George A Karpouzas<br />
Time to Discontinuation and Effectiveness with Baricitinib<br />
in Rheumatoid Arthritis: 12-Month European Data from a<br />
Multinational, Prospective, Observational Study<br />
Rieke Alten<br />
Outcomes in Patients with Rheumatoid Arthritis Initiating<br />
Monotherapy with Etanercept, Adalimumab, or Janus Kinase<br />
Inhibitors<br />
Dimitrios Pappas<br />
Impact of Upadacitinib versus Abatacept on Individual Disease<br />
Outcomes in Patients with Rheumatoid Arthritis and Inadequate<br />
Responses to Biologic DMARDs<br />
Ronald F. Van Vollenhoven<br />
Acute Cardiovascular Events Risk in Rheumatoid Arthritis<br />
Patients Treated with Tofacitinib or TNF Inhibitors, a Nationwide<br />
Cohort Study: RELATION Study<br />
Jacques-Eric Gottenberg<br />
Impact of Tofacitinib on Fracture Risk in Rheumatoid Arthritis<br />
Giovanni Adami<br />
O<strong>RA</strong>L SESSION<br />
<strong>RA</strong> – TREATMENT I: SWITCHING OR<br />
DISCONTINUATION OF THE<strong>RA</strong>PIES<br />
Sustained Remission Following the Discontinuation of<br />
Tofacitinib in Patients with Rheumatoid Arthritis (XANADU<br />
Study): A Multicenter, Prospective, and Randomized Controlled<br />
Study<br />
Satoshi Kubo<br />
O<strong>RA</strong>L SESSION<br />
<strong>RA</strong> – TREATMENT I: SWITCHING OR<br />
DISCONTINUATION OF THE<strong>RA</strong>PIES<br />
Outcomes of Etanercept and Janus Kinase Inhibitor Treatment<br />
After First-line Use of Adalimumab in Patients with Rheumatoid<br />
Arthritis<br />
Dimitrios Pappas<br />
O<strong>RA</strong>L SESSION<br />
<strong>RA</strong> – TREATMENT I: SWITCHING OR<br />
DISCONTINUATION OF THE<strong>RA</strong>PIES<br />
Pain and Treatment Switching Among Patients in the<br />
CorEvitasTM Rheumatoid Arthritis Registry<br />
Joshua Baker<br />
Monday, 14 November <strong>2022</strong><br />
09:30–<br />
09:40<br />
L03<br />
10:15–<br />
10:25<br />
L06<br />
13:00–<br />
15:00<br />
1765<br />
13:00–<br />
15:00<br />
1984<br />
1985<br />
1995<br />
2008<br />
2015<br />
O<strong>RA</strong>L SESSION<br />
LATE-BREAKING ABST<strong>RA</strong>CTS (L01–L06)<br />
A Phase 2 Trial of Peresolimab for Adults with Rheumatoid<br />
Arthritis<br />
Paul Emery<br />
O<strong>RA</strong>L SESSION<br />
LATE-BREAKING ABST<strong>RA</strong>CTS (L01–L06)<br />
Risk of Extended Major Adverse Cardiovascular Event<br />
Endpoints with Tofacitinib vs TNF Inhibitors in Patients with<br />
Rheumatoid Arthritis: A Post Hoc Analysis of a Phase 3b/4<br />
Randomized Safety Study<br />
Maya Buch<br />
POSTER SESSION<br />
EPIDEMIOLOGY AND PUBLIC HEALTH POSTER III<br />
Safety of the Recombinant Herpes Zoster Vaccine in Patients<br />
with Rheumatoid Arthritis Treated with JAKi Drugs<br />
Ana Pons<br />
POSTER SESSION<br />
<strong>RA</strong> – TREATMENT POSTER IV<br />
Malignancies Risk in Rheumatoid Arthritis Patients Treated with<br />
Tofacitinib or TNF Inhibitors, a National Study: RELATION Study<br />
Jacques-eric Gottenberg<br />
The BEGIN Study: A Double-blind, Multi-center, Two-part,<br />
Randomized, Placebo-controlled Study of the Safety,<br />
Tolerability, and Efficacy of 4 Weeks of Treatment with AP1189<br />
in Early Rheumatoid Arthritis (<strong>RA</strong>) Patients with Active Joint<br />
Disease<br />
Thomas Jonassen<br />
Baricitinib Improves Bone Biomechanical Properties in<br />
Rheumatoid Arthritis (<strong>RA</strong>) – Results of a Prospective<br />
Interventional Study<br />
Arnd Kleyer<br />
A Phase 2, Randomized, Double-Blind, Placebo-Controlled,<br />
Mechanistic Insight and Dosage Optimization Study of the<br />
Efficacy and Safety of Dazodalibep (VIB4920/HZN4920)<br />
in Patients with Rheumatoid Arthritis Having Inadequate<br />
Response to Conventional/Biological DMARDs<br />
Alan Kivitz<br />
JAK Selectivity Did Not Affect to the Incidence of Malignancies<br />
in the Real-World Setting: Data from a Multicenter<br />
Observational Study in Japan<br />
Tomohisa Uchida
Change language